Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Great Novel Therapeutics Biotech & Medicals (7427.TWO)

36.95
-1.20
(-3.15%)
At close: 2:59:59 PM GMT+8
Currency in TWD All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
615
1,685
4,850
540
630
Cost of Revenue
2,435
670
43
76
347
Gross Profit
-1,820
1,015
4,807
464
283
Operating Expense
91,976
113,662
70,627
57,902
36,804
Operating Income
-93,796
-112,647
-65,820
-57,438
-36,521
Net Non Operating Interest Income Expense
6,303
7,664
5,243
936
515
Pretax Income
-87,972
-104,924
-60,997
-55,779
-35,857
Net Income Common Stockholders
-87,972
-104,924
-60,997
-55,779
-35,857
Diluted NI Available to Com Stockholders
-87,972
-104,924
-60,997
-55,779
-35,857
Basic EPS
-2.55
--
-1.68
-2.22
-1.49
Diluted EPS
-2.55
--
-1.68
-2.22
-1.49
Basic Average Shares
41,146.67
--
36,307.74
27,628.21
24,845.18
Diluted Average Shares
41,146.67
--
36,307.74
27,628.21
24,845.18
Total Expenses
94,411
114,332
70,670
57,978
37,151
Net Income from Continuing & Discontinued Operation
-87,972
-104,924
-60,997
-55,779
-35,857
Normalized Income
-87,972
-104,924
-60,997
-55,779
-35,857
Interest Income
6,446
7,789
5,334
936
515
Interest Expense
143
125
91
--
--
Net Interest Income
6,303
7,664
5,243
936
515
EBIT
-87,829
-104,799
-60,906
-55,779
-36,521
EBITDA
-78,978
-97,862
-56,564
-53,957
-35,022
Reconciled Cost of Revenue
2,435
670
43
76
347
Reconciled Depreciation
8,851
6,937
4,342
1,822
1,499
Net Income from Continuing Operation Net Minority Interest
-87,972
-104,924
-60,997
-55,779
-35,857
Normalized EBITDA
-78,978
-97,862
-56,564
-53,957
-35,022
12/31/2021 - 7/8/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers